is Partner at
Adjuvant Global Advisors.
Adjuvant Global Advisors is a business development consulting firm serving pharmaceutical and biotech clients. They provide search and evaluation to pharma clients; complete business development services for biotech clients; and alliance development and strategy consulting to disease foundations.
Jeff has over 20 years of experience in biotechnology business development and commercialization strategy. Much of his recent work has been in transaction advisory services and alliance development, including in-licensing, partnering, and commercialization of preclinical, clinical, and marketed pharmaceutical products.
He has served as the CEO of Innovative Biologics, Inc, a small molecule anti-infectives company developing inhibitors of pore-forming toxins for Methicillin Resistant Staphylococcus aureus (MRSA) infection. Prior to Adjuvant, he held general management and marketing leadership positions with Thermo BioAnalysis, a division of Thermo Electron (NYSE:TMO). Prior to Thermo, he held sales, marketing and business development positions at Transgenic Sciences Corp. and Abbott Laboratories.
Jeff is a member of the Licensing Executives Society and serves on the Board of the Virginia Biotechnology Association. He holds adjunct faculty appointments at Georgetown University Medical School and Virginia Polytechnic Institute and State University. He earned a BS in Finance from Providence College in 1988.
Read his LinkedIn profile.